Save time and get answers to complex questions with AI chat
What is the difference between apixaban and apixaban accord?What excipients are combined with ruxolitinib in apotex's medication?Guselkumab brand name?How long have hydroxyzine pamoate been on the market?Dabrafenib patent expiration date novartis gsk composition matter?
See the DrugPatentWatch profile for polivy
Who participated in Polivy's clinical trials? Polivy, also known as tiragolumab, is an experimental cancer treatment developed by AstraZeneca and Daiichi Sankyo Co. Clinical trials for Polivy have been conducted in various age groups. According to [1] AstraZeneca's website, Polivy has been studied in patients with non-small cell lung cancer (NSCLC), who are typically 18 years or older, including those with a history of smoking or a history of other cancers. [2] Another clinical study [3], focused on patients 60 to 90 years old and included both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Sources: [1] AstraZeneca. Tiragolumab (AMG 211) [internet].; 2022 [cited 2023]. Available from: https://www.astrazeneca.com/our-business/research-discovery/our-pipeline/tiragolumab-amg-211.html [2] NCT04636619 – Clinical Trials.gov [3] A Study to Evaluate the Efficacy and Safety of Tiragolumab in Combination With Durvalumab and Etoposide in Participants With Extensive-stage Small Cell Lung Cancer Note: There is no information about age ranges of under 18 involved in clinical studies.
Other Questions About Polivy :